Navigation Links
Possible safer target for anti-clotting drugs found

Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents.

The findings are reported in the September issue of Molecular and Cellular Biology.

"It was very surprising to find an enzyme whose inhibition lessened platelet aggregation without abnormal bleeding, and we immediately realized that it could have very important implications for the treatment of cardiovascular disease," said Shafi Kuchay, a graduate student in pharmacology and first author of the paper.

When clots form, small blood cells called platelets begin to clump together. Aspirin and other anti-clotting agents reduce the risk of heart attack and stroke by blocking the biochemical pathway that causes platelets to become sticky. But all these drugs put patients at risk of excessive bleeding.

The UIC researchers made a mouse model that lacked a gene for a protease enzyme most commonly found in blood cells called calpain-1, in order to determine its function. They found that mice lacking calpain-1 had reduced platelet aggregation but did not have any abnormal bleeding.

The mice lacking calpain-1 (called "knockout" mice) had increased levels of another enzyme, known as protein tyrosine phosphatase-1B. When the mice were given a PTP1B inhibitor, the reduced platelet aggregation was restored. When calpain-1 knockout mice and mice lacking PTP1B were crossed to create double-knockout mice, platelet aggregation was restored in the offspring that lacked the genes for both enzymes. The researchers were thus able to establish that PTP1B turns off the signal for platelet aggregation and that calpain-1 regulated the amount and activity of this "off switch."

"Because of the danger of excessive bleeding, people taking anti-clotting medications are monitored carefully and warned not to exceed their recommended doses," said Dr. Athar Chishti of the UIC Cancer Center, and senior author of the study. "Our research unveils a new molecular target for anti-platelet drugs, which may avoid the dangerous side-effects of the current drugs."

In a secondary, serendipitous finding, the fact that the calpain-1 knockout mice have elevated PTP1B levels may prove important to research into diabetes and obesity.

"Mice that lack the gene for PTP1B have been known for some time to display increased insulin sensitivity and resistance to diet-induced obesity," said Chishti, who is professor of pharmacology. He noted that PTP1B inhibition has already been identified as a therapeutic goal by many researchers in diabetes and obesity.

"Our calpain-1 knockout mice with their elevated PTP1B levels offer a good model system for testing the potency of novel PTP1B inhibitors," he said.


Contact: Jeanne Galatzer-Levy
University of Illinois at Chicago

Related medicine news :

1. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
2. Early diagnosis for autism from blood tests may be possible
3. Borderline blood pressure- possible health risk
4. Depression a possible danger in elderly
5. Possible benefits of Hormone Replacement Therapy
6. Use of zinc supplements tied to possible increase in risk of prostate cancer
7. Return of SARS possible this fall
8. Low Protein Levels A Possible Indicator For A Miscarriage
9. Cure For Persistent Oral Fungal Problem May Be Possible
10. Transfer Of Rabies Virus Possible From Organ Donor To Recipient
11. New treatment possible for drug addiction
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology: